Early Progressive Strength Exercise for Treatment of Acute Achilles Tendon Rupture.

June 7, 2023 updated by: Marianne Christensen, Aalborg University Hospital

A Randomized Controlled Trial on the Effect of Early Progressive Strength Exercise for Treatment of Acute Achilles Tendon Rupture. The Achilles Tendon Back-On-Track Study.

The purpose of this trial is to investigate the efficacy of standard care versus standard care combined with an early progressive exercise program in improving the function of the tendon and leg muscles after non-surgical treated Achilles tendon rupture

Study Overview

Detailed Description

Acute Achilles tendon rupture often results in long-term muscular deficits. Patients struggle to return to work and sports with high load on the lower leg. Early functional rehabilitation has shown good results, but research on resistance exercise is scarce and the reporting of the specifics of the exercises are poor.

Study Type

Interventional

Enrollment (Estimated)

82

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Aalborg, Denmark, 9000
        • Orthopeadic department, Physiotherapy and Occupational Therapy, Aalborg University Hospital
      • Hjørring, Denmark, 9800
        • Orthopeadic department, Physiotherapy and Occupational Therapy, North Denmark Regional Hospital Hjørring

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Acute total Achilles tendon rupture treated non-surgically
  • Diagnosed within 3 days (of their injury)
  • Age 18 - 65, able and willing to participate in the intervention
  • Able to speak and understand Danish

Exclusion Criteria:

  • Achilles tendon rupture close to insertion on calcaneus or in the musculo-tendinous junction of the triceps surae
  • Previous Achilles tendon rupture or other conditions in either leg causing lower leg disability (pain, deficits in strength or range of movement)
  • Treated with Fluoroquinolons or Corticosteroids within the last 6 months
  • Diabetes or rheumatic diseases
  • Severe medical illness: ASA score higher than or equal to 3. (ASA: American Society of Anesthesiologists physical status classification system)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Standard care exercises
This is the currently used treatment in the nine weeks of immobilisation with an orthosis.
Consists of a a standard exercise program with range of motion exercises from the third week and elastic band exercise from the sixth week.
Experimental: Early progressive strength exercise
This exercise program initiates early (second week) and continues with resistance exercises with progression of the load according to individual participant toleration.
This exercise program consists of standard exercises plus the early progressive program that initiates early (second week) and continues with resistance exercises with progression of the load according to individual participant toleration. Exercises are isometric exercises from the second week and then gradually progression of load in seated heel-rise and resistance band exercises.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Achilles tendon total rupture score ATRS
Time Frame: 13 weeks
Validated patient reported outcome measure. It contains 10 questions about physical performance in an 11-point Likert scale from zero to ten.
13 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Achilles tendon total rupture score ATRS
Time Frame: Baseline, 26 and 52 weeks
Validated patient reported outcome measure. It contains 10 questions about physical performance in an 11-point Likert scale from zero to ten.
Baseline, 26 and 52 weeks
International Physical Activity Questionnaire (IPAQ)
Time Frame: baseline, 13, 26 and 52 weeks
International Physical Activity Questionnaire (IPAQ) short form Danish version. It consists of 7 items concerning physical activity as time spent performing vigorous and moderate activities, the time spent walking and sitting during the past week. The IPAQ gives an estimate of the total weekly physical activity measured in MET-minutes per week and total minutes spent sitting.(MET: The Metabolic Equivalent of Task)
baseline, 13, 26 and 52 weeks
Achilles tendon resting angle (ATRA)
Time Frame: 13 and 52 weeks
ATRA is validated as an indirect measure of the Achilles tendon length
13 and 52 weeks
Achilles tendon length
Time Frame: 9, 13 and 52 weeks
Ultrasound measure of achilles tendon length using Copenhagen Achilles length measure (CALM)
9, 13 and 52 weeks
Isometric muscle strength
Time Frame: 9, 13 and 52 weeks
maximal isometric plantar flexor muscle strength using a Fysiometer
9, 13 and 52 weeks
Muscle endurance
Time Frame: 13 and 52 weeks
Muscle endurance is measured in seated or standing heel-rise with MuscleLab Measurement system (Ergotest Technology, Oslo, Norway)
13 and 52 weeks
The fear of re-rupture
Time Frame: 9, 13 and 52 weeks
The Tampa scale of Kinesiophobia (TSK) is a questionaire consisting of 17 items concerning pain and kinesiophobia and has 4 answers from "Strongly disagree" to "Strongly agree".
9, 13 and 52 weeks
Adverse events
Time Frame: 9, 13 and 52 weeks
The number of serious and minor adverse events is registered in a pre-defined list based on Common Terminology Criteria for Adverse Events
9, 13 and 52 weeks
Compliance
Time Frame: 9 weeks
The participants will register the number of exercise sessions they perform each day in a training journal.
9 weeks

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cost-effectiveness outcomes
Time Frame: 9, 13, 26 and 52 weeks
Work Productivity and Activity Impairment Questionnaire WPAI:GH and condition-related expenses as measured by a self-developed questionnaire
9, 13, 26 and 52 weeks
Self-reported health state
Time Frame: Baseline, 9, 13, 26, 52 weeks
EQ-5D-5L is a generic health-related quality of life instrument
Baseline, 9, 13, 26, 52 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Marianne Christensen, MHSc, Aalborg University Hospital, Denmark
  • Study Chair: Inge Lunding Kjær, MD, Aalborg University Hospital, Denmark
  • Study Chair: Jennifer A Zellers, PhD, Washington University School of Medicine in St. Louis, USA
  • Study Chair: Karin Grävare Silbernagel, PhD, University of Delaware, DE USA
  • Study Chair: Michael Skovdal Rathleff, PhD, Aalborg University Hospital, Denmark

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 19, 2021

Primary Completion (Actual)

January 30, 2023

Study Completion (Estimated)

November 1, 2023

Study Registration Dates

First Submitted

January 23, 2021

First Submitted That Met QC Criteria

January 23, 2021

First Posted (Actual)

January 27, 2021

Study Record Updates

Last Update Posted (Actual)

June 8, 2023

Last Update Submitted That Met QC Criteria

June 7, 2023

Last Verified

June 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • N-20200041

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Data will be available upon reasonable request

IPD Sharing Time Frame

After completion of the 1 year follow-up

IPD Sharing Access Criteria

Researchers that provide a methodologically sound plan

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Achilles Tendon Rupture

Clinical Trials on Standard exercises

3
Subscribe